(IN BRIEF) Researchers at The Institute of Cancer Research, London, have developed WIN-DOSE, a proposed clinical-trial design to support more transparent and patient-centred selection of cancer drug doses in early-stage studies. The method enables researchers to establish a clear hierarchy … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged cancer drug development, cancer research, Cancer Research UK, Christina Yap, Clinical Cancer Research, clinical trial statistics, clinical trials, dose optimisation, dose selection, Drug Safety, early-stage clinical trials, Emily Alger, ICR, New Statistical Design Aims to Strengthen Evidence-Based Dose Decisions in Cancer Research, oncology, patient-centred research, patient-reported outcomes, Patient-Reported Outcomes Feature in New Framework for Selecting Cancer Drug Doses, pharmacodynamics, pharmacokinetics, precision medicine, The Institute of Cancer Research, treatment efficacy, treatment tolerability, United Kingdom, WIN-DOSE
(IN BRIEF) ESC Congress 2026 will take place in Munich from 28 to 31 August, bringing together more than 30,000 clinicians and scientists from over 150 countries to discuss cardiovascular research, clinical trials, digital health and new treatment approaches. Artificial … Read the full press release
Posted in Artificial Intelligence (AI), Education, France, Healthcare, Media, Science, Technology
Tagged AI in healthcare, artificial intelligence, Artificial Intelligence and Clinical Practice Take Centre Stage at ESC Congress 2026, cardiology, cardiovascular disease, clinical decision making, Clinical Practice, clinical trials, Clinicians, digital cardiology, digital health, Early Detection, ESC, ESC Congress 2026, ESC Congress 2026 Will Present New Guidelines and Emerging Innovations in Heart Health, ESC guidelines, European Society of Cardiology, evidence-based medicine, Germany, Global Cardiology Community to Gather in Munich for ESC Congress 2026, Healthcare Innovation, heart health, Hot Line sessions, Machine Learning, medical congress, medical imaging, medical research, mobile health applications, Munich, New Horizons Track, patient care, Patient’s Perspective Track, prevention, Professor Filippo Crea, rehabilitation, risk prediction, scientists
(IN BRIEF) The University of Liverpool has won the Best Public Sector Innovation award at the 2026 Prix Galien UK Awards for its three major COVID-19 response innovations: the SMART community testing programme, the ISARIC clinical characterisation study and the … Read the full press release
Posted in Awards, Education, European Union, Government, Healthcare, Pharma & Biotech, Science, Security & Safety, Society, Technology, United Kingdom
Tagged 4C Mortality Score, AGILE therapeutics trial platform, antiviral treatments, asymptomatic testing, Best Public Sector Innovation, British Army, case detection, Cheshire and Merseyside, CIPHA, Civic Health Innovation Labs, clinical characterisation study, clinical trials, Combined Intelligence for Population Health Action, community testing, COVID-19 hospitalisations, Covid-19 pandemic, Data into Action, Gary Leeming, health data infrastructure, International Severe Acute Respiratory and Emerging Infection Consortium, ISARIC, lateral flow devices, Liverpool, Liverpool City Council, Liverpool COVID-19 Drug Interactions tool, Liverpool COVID-19 Response Trio Wins Best Public Sector Innovation at 2026 Prix Galien UK Awards, London, mass testing, molnupiravir, Natural History Museum, NERVTAG, NHS, nirmatrelvir ritonavir, pandemic response, Prix Galien UK Awards, Professor Calum Semple, Professor Iain Buchan, Professor Lauren Walker, Professor Marta Garcia-Finana, Professor Richard FitzGerald, Professor Saye Khoo, Professor Sir Munir Pirmohamed, public health innovation, remdesivir, Sage, SMART programme, Systematic Meaningful Asymptomatic Repeated Testing, University of Liverpool, University of Liverpool Wins Prix Galien UK Award for Landmark COVID-19 Public Sector Innovation, University of Liverpool wins Prix Galien UK award for three major COVID-19 response innovations, University of Liverpool’s SMART ISARIC and AGILE Programmes Recognised With Prix Galien UK Honour, vaccine development, WHO, World Health Organisation
(IN BRIEF) Boehringer Ingelheim has received approval from Japan’s Ministry of Health, Labour and Welfare for JASCAYD® (nerandomilast) to treat adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The oral PDE4B inhibitor is the first therapy of its kind … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged antifibrotic treatment, Arata Azuma, Boehringer Ingelheim, clinical trials, FIBRONEER, fibrosis treatment, forced vital capacity, idiopathic pulmonary fibrosis, immunomodulatory therapy, IPF, Japan Ministry of Health Labour and Welfare, JASCAYD, lung disease, lung function decline, MHLW, nerandomilast, PDE4B inhibitor, pharmaceutical industry, PPF, progressive pulmonary fibrosis, pulmonary fibrosis, rare diseases, respiratory health, respiratory medicine, Shashank Deshpande
(IN BRIEF) Roche has agreed to acquire PathAI to strengthen its digital pathology and AI-powered diagnostics capabilities. The deal builds on an existing partnership between the companies focused on AI-enabled companion diagnostics and pathology solutions. Roche said the acquisition will … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI diagnostics, AI-powered pathology, AISight, Andy Beck, artificial intelligence, Biomarker Development, biomarker discovery, Biopharma Industry, cancer diagnosis, clinical trials, companion diagnostics, Diagnostic Tools, diagnostics division, digital pathology, Healthcare Innovation, healthcare technology, image management system, laboratory automation, Matt Sause, medical AI, medical imaging, oncology diagnostics, PathAI, pathology laboratories, pathology software, personalized healthcare, pharmaceutical industry, precision medicine, Roche, Roche and PathAI Combination Aims to Accelerate Personalized Cancer Diagnostics and Biomarker Discovery, Roche Deepens Investment in Artificial Intelligence Through Planned PathAI Acquisition, translational research
(IN BRIEF) Luxembourg’s Parkinson’s community celebrated ten years of collaborative progress in research and patient care through a dedicated event that brought together participants, families, clinicians, and scientists. Organized in a World Café format, the gathering encouraged open discussions on … Read the full press release
Posted in Business, Healthcare, Industrial, Investment, Luxembourg, Management, Science, Technology
Tagged clinical trials, digital medicine, healthcare collaboration, Luxembourg Marks Ten Years of Collaborative Parkinson’s Research and Care with Community Driven World Café Event, Luxembourg Parkinson’s research, Luxembourg research ecosystem, Luxembourg Strengthens Its Role in Parkinson’s Research Through Decade Milestone Event and Ongoing Collaboration, NCER-PD, neurodegenerative disease research, neurological research, ParkinsonNet Luxembourg, patient participation, precision medicine, Rejko Krüger, Stéphanie Obertin, University of Luxembourg
(IN BRIEF) AstraZeneca has secured FDA approval for a new subcutaneous autoinjector version of Saphnelo, enabling once-weekly self-administration for adults with systemic lupus erythematosus. The approval is based on Phase III trial results showing significant reductions in disease activity compared … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged anifrolumab, AstraZeneca, AstraZeneca introduces new subcutaneous Saphnelo delivery method to improve convenience and outcomes in lupus care, autoimmune disease, autoinjector, biologic therapy, Bristol-Myers Squibb, clinical trials, FDA, Healthcare Innovation, Louise Vetter, Lupus Foundation of America, Medarex, Ruud Dobber, Saphnelo, SLE, Susan Manzi, systemic lupus erythematosus, TULIP-SC, U.S. Food and Drug Administration
(IN BRIEF) The European Investment Bank has provided €100 million in financing to Orion Pharma to support the development of new treatments for cancer, pain, and other conditions with limited therapeutic options. The funding will be used for research and … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Finland, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical industry, clinical trials, Critical Medicines Alliance, drug development, EIB, EU resilience, European Investment Bank, European Investment Bank and Orion Pharma Expand Collaboration to Boost Healthcare Innovation and Supply Security, Healthcare Innovation, Karl Nehammer, oncology, Orion Pharma, pain treatment, pharmaceutical research, R&D investment, René Lindell, €100 Million EIB Investment Supports Orion Pharma Development of Critical Medicines and Therapies
(IN BRIEF) Sanofi and Regeneron have received European Commission approval for Dupixent to treat children aged two to 11 with chronic spontaneous urticaria, marking the first targeted therapy available for this condition in young patients. Supported by data from the … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Alyssa Johnsen, biologics, chronic spontaneous urticaria, clinical trials, CSU, CUPIDKids, dupilumab, Dupixent, EU approval, European Commission, George D. Yancopoulos, immunology, LIBERTY CUPID, pediatric dermatology, pediatric treatment, Regeneron Pharmaceuticals, Sanofi, Sanofi and Regeneron Advance Pediatric Care with EU Approval of Dupixent for Chronic Spontaneous Urticaria, type 2 inflammation
(IN BRIEF) Sanofi has announced positive phase 2 clinical results for lunsekimig, a novel bispecific therapy targeting key inflammatory pathways in respiratory diseases. The treatment successfully met primary and key secondary endpoints in studies involving moderate-to-severe asthma and chronic rhinosinusitis … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged asthma treatment, atopic dermatitis, biologic therapy, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, drug development, Houman Ashrafian, IL13, lunsekimig, Nanobody VHH, Phase 2 study, respiratory diseases, Sanofi, Sanofi Advances Respiratory Pipeline with Promising Clinical Data for Dual Targeting Lunsekimig Therapy, Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Respiratory Diseases Development, TSLP
(IN BRIEF) The University of Southampton is celebrating 25 years of EDGE, a clinical research management system developed by its Clinical Informatics Research Unit. Originally created to improve coordination and data access for research teams, EDGE is now widely used … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, Science, Technology, United Kingdom
Tagged Cancer Research UK, Carly Ringrose, CIRU, Clinical Informatics Research Unit, clinical research, clinical trials, data quality, digital health, EDGE Celebrates Silver Jubilee as Global Platform Supporting Faster and More Accurate Medical Research, EDGE system, global research collaboration, healthcare technology, James Batchelor, medical data, NHS, patient care, research management software, University of Southampton
(IN BRIEF) GSK has announced that China’s National Medical Products Administration has accepted for review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide designed to treat adults with chronic hepatitis B. The submission is supported by Phase III … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Science, United Kingdom
Tagged antisense oligonucleotide, ASO therapy, B-Well 1 trial, B-Well 2 trial, Bepirovirsen, breakthrough therapy designation, CHB, China healthcare, chronic hepatitis B, clinical trials, drug development, functional cure, GSK Moves Closer to Transforming Chronic Hepatitis B Care with Bepirovirsen NDA Review in China, GSK plc, GSK Strengthens Infectious Disease Portfolio with Regulatory Submission for Novel Hepatitis B Therapy in China, HBsAg, hepatitis B surface antigen, infectious disease, liver cancer, National Medical Products Administration, NMPA, viral infection
(IN BRIEF) GSK has secured approval in China for Exdensur (depemokimab), a first-of-its-kind ultra-long-acting biologic for treating severe eosinophilic asthma in patients aged 12 and above. Approved by China’s National Medical Products Administration, the therapy offers a novel treatment approach … Read the full press release
Posted in Business, Healthcare, Marketing, Pharma & Biotech, Science, United Kingdom
Tagged asthma exacerbations, asthma treatment, biologic therapy, biologics, China healthcare, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, Depemokimab, eosinophilic asthma, Exdensur, GSK Advances Asthma Treatment Innovation with NMPA Approval of Exdensur for Eosinophilic Severe Asthma in China, GSK Introduces Ultra-Long-Acting Biologic Exdensur to Address Severe Asthma Burden in China Healthcare System, GSK plc, Kaivan Khavandi, National Medical Products Administration, NMPA, respiratory disease, Severe Asthma, SWIFT-1 trial, SWIFT-2 trial, type 2 inflammation
(IN BRIEF) GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early clinical data showing durable responses in patients with extensive-stage disease. SCLC, … Read the full press release
Posted in Business, Healthcare, Marketing, Pharma & Biotech, Science, Security & Safety, United Kingdom
Tagged antibody-drug conjugate, ARTEMIS-001, B7-H3, breakthrough therapy designation, clinical trials, colorectal cancer, EMA, ES SCLC, extensive stage SCLC, FDA, GSK, GSK advances investigational cancer therapy risvutatug rezetecan with sixth global designation supporting development in solid tumours, Hansoh Pharma, Japan Ministry of Health Labour and Welfare, lung cancer, oncology, orphan drug designation, Phase III Trial, PRIME designation, prostate cancer, Ris Rez, risvutatug rezetecan, SCLC, Small cell lung cancer
(IN BRIEF) Sanofi has received Breakthrough Therapy designation from the US FDA for venglustat, an investigational oral drug targeting neurological symptoms of type 3 Gaucher disease, a rare genetic disorder with no approved treatments for its neurological manifestations. The designation … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged biotechnology, clinical trials, enzyme replacement therapy, Fast Track Designation, FDA, Gaucher disease type 3, GD3, imiglucerase, Karin Knobe, LEAP2MONO, lysosomal storage disorder, orphan drug, rare disease, Sanofi, Sanofi Strengthens Pipeline with Venglustat Following FDA Breakthrough Designation for Rare Neurological Disorder, US Food and Drug Administration, venglustat
(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 35Pharma, activin signalling inhibitor, biotechnology acquisition, CANADA, cardiopulmonary diseases, clinical trials, drug development, GSK, GSK Targets Next Generation Pulmonary Hypertension Treatments with Acquisition of 35Pharma, GSK to Acquire 35Pharma for 950 Million Dollars to Strengthen Pulmonary Hypertension Drug Pipeline, HS235, Ilia Tikhomirov, PH-HFpEF, pharmaceutical industry, pulmonary arterial hypertension PAH, pulmonary hypertension, Respiratory Immunology and Inflammation portfolio, Tony Wood
(IN BRIEF) Sanofi has received Breakthrough Therapy designation from the U.S. FDA and orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for rilzabrutinib (Wayrilz) in warm autoimmune hemolytic anemia, based on data from the ongoing LUMINA 2 … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Retail, Science, Security & Safety, Technology
Tagged Breakthrough Therapy, BTK inhibitor, clinical trials, FDA, FDA Grants Breakthrough Status to Sanofi’s Rilzabrutinib for Rare Blood Disorder, IgG4-related disease, immune thrombocytopenia, Japanese Ministry of Health Labour and Welfare, Karin Knobe, LUMINA 2, LUMINA 3, orphan drug, rare diseases, rilzabrutinib, Sanofi, Sanofi Advances Rilzabrutinib with Breakthrough and Orphan Designations in wAIHA, sickle cell disease, Tailored Covalency®, wAIHA, warm autoimmune hemolytic anemia, Wayrilz
(IN BRIEF) Sanofi has received a positive recommendation from the European Medicines Agency’s CHMP for the conditional approval of Rezurock to treat late-line chronic graft-versus-host disease in adults and adolescents aged 12 and older. The opinion, based on clinical trial … Read the full press release
Posted in European Union, France, Healthcare, Marketing, Pharma & Biotech
Tagged belumosudil, CHMP, CHMP Recommends Conditional EU Authorisation for Sanofi’s Rezurock to Treat Late-Line Chronic GVHD, chronic graft-versus-host disease, clinical trials, conditional marketing authorisation, EU regulatory approval, European Medicines Agency, GVHD, haematology, rare diseases, Rezurock™, ROCK2 inhibitor, ROCKstar study, Sanofi, stem cell transplant
(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release
Posted in Belgium, Business, Germany, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, ATMP, autoimmunity, BioNTech, BioNTech’s BNT116, biotechnology, Cancer Vaccine Launch Pad, CAR-T therapy, clinical trials, CREATE Medicines, CureVac, EMA, EU-FAB, Europe, Europe Becomes a Hub for Next-Generation RNA Immunotherapy with Strong Clinical and Industrial Momentum, Europe’s Biotech Sector Accelerates RNA-Based Immunotherapy with Breakthroughs in CAR-T and mRNA Vaccines, Europe’s RNA Immunotherapy Industry Poised for Expansion as BioNTech AstraZeneca and CREATE Medicines Lead Advances, Europe’s RNA Immunotherapy Landscape Expands with First In Vivo CAR-T Trial and Growing mRNA Vaccine Efforts, Europe’s RNA Immunotherapy Pipeline Gains Scale as Regulators and Industry Push for Next-Gen Cancer Treatments, fibrosis, Germany, Imfinzi, immuno-oncology, in vivo CAR-T, INT2104, mRNA Vaccines, multi-lineage immune programming, Myeloid Therapeutics, NHS England, oncology, pharma, RNA immunotherapy, RNA Immunotherapy in Europe: Emerging Trials Strategic Mergers and a Clearer Regulatory Path, RNA Immunotherapy Takes Hold in Europe as BioNTech-CureVac Deal and CREATE Medicines Expansion Signal Maturity, RNA therapeutics, RNA-based therapies, United Kingdom
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?